Showing 1371-1380 of 2526 results for "".
- University of Oklahoma Study Identifies 20 Novel Variants for Inherited Retinal Diseaseshttps://modernod.com/news/university-of-oklahoma-study-identifies-20-novel-variants-for-inherited-retinal-diseases/2482824/A new study out of the University of Oklahoma maps 20 new gene mutations contributing to rare inherited retinal diseases (IRDs). Researchers aim to use these findings to improve diagnostic accuracy and identify targets for future
- Alcon Launches UNITY VCS and UNITY CS for for Vitreoretinal and Cataract Surgeryhttps://modernod.com/news/alcon-launches-unity-vcs-and-unity-cs-for-for-vitreoretinal-and-cataract-surgery/2482763/Alcon announced the launch of the UNITY Vitreoretinal Cataract System (VCS) and UNITY Cataract System (CS). The platform offers two configurations, a combined console (VCS) as well as a standalone cataract system (CS). It is designed to deliver superior efficiency for vit
- University of Cincinnati Study Finds Fear of Vision Loss is a Barrier to Cataract Surgeryhttps://modernod.com/news/university-of-cincinnati-study-finds-fear-of-vision-loss-is-a-barrier-to-cataract-surgery/2482761/Fear of vision loss, particularly among patients who have a visually significant cataract in only one eye, may deter some from undergoing cataract surgery, according to a new study from the Department of Ophthalmology at the University of Cincinnati (UC). The study,
- Unity Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in DMEhttps://modernod.com/news/unity-biotechnology-announces-topline-results-from-the-aspire-phase-2b-study-in-dme/2482712/Unity Biotechnology announced topline results from the phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment. The study results include data from all patients through 24 weeks, and the majori
- Mount Sinai Team Identifies Underlying Mechanisms of Age-Related Meibomian Gland Dysfunction, Possible Treatment Options for Dry Eye Diseasehttps://modernod.com/news/mount-sinai-team-identifies-underlying-mechanisms-of-age-related-meibomian-gland-dysfunction-possible-treatment-for-dry-eye-disease/2482679/New research from Mount Sinai identifies an underlying molecular mechanism of age-related degeneration in the meibomian glands essential to normal eye function. Now, this may lead to new therapeutic approaches for common conditions in older adults such as evaporated dry eye disease.
- Formycon Receives EU Approval for Eylea Biosimilar FYB203 Under the Brand Names Ahzantive and Baiamahttps://modernod.com/news/formycon-receives-eu-approval-for-eylea-biosimilar-fyb203-under-the-brand-names-ahzantive-and-baiama/2482624/Formycon and its licensing partner Klinge Biopharma jointly announce that the European Commission has granted central marketing authorization for FYB203 (aflibercept), a biosimilar to Eylea, under the brand names Ahzantive and Baiama. The app
- Bausch + Lomb Launches enVista Aspire Monofocal and Toric IOLs in the European Unionhttps://modernod.com/news/bausch-lomb-launches-envista-aspire-monofocal-and-toric-iols-in-the-european-union/2482610/Bausch + Lomb announced the commercial launch of the enVista Aspire monofocal and toric IOLs in the European Union after receiving a CE Mark late last year. According to B+L, enVista Aspire combines 'intermediate optimized' optics, which are designed for a broader dept
- Bausch + Lomb’s Recycling Programs Collect Over 94 Million Units of Eye Care Waste in the UShttps://modernod.com/news/bausch-lombs-recycling-programs-collect-over-94-million-units-of-eye-care-waste-in-the-us/2482541/Bausch + Lomb announced a milestone in its sustainability efforts—the company's exclusive recycling initiatives, ONE by ONE Recycling and Biotrue Eye Care Recycling programs, have successfully collected a total of 94,119,275 units of used contact lenses, eye care, and lens care material
- Genentech Announces Phase 4 Results for Vabysmo in Treating DME Among Underrepresented Populationshttps://modernod.com/news/genentech-announces-phase-4-results-for-vabysmo-in-treating-dme-among-underrepresented-populations/2482514/Genentech revealed promising 1-year findings from its phase 4 ELEVATUM study for Vabysmo (faricimab-svoa) for diabetic macular edema (DME) in racial and ethnic groups typically underrepresented in clinical trials. Results presented at the American Academy of Ophthalmology (AAO) 2024 annual m
- New Study Unveils How Immune Cells Defend the Eye Against Inflammationhttps://modernod.com/news/new-study-unveils-how-immune-cells-defend-the-eye-against-inflammation/2482470/In a new study, researchers led by Sue Menko, PhD, of Thomas Jefferson University, have revealed how immune cells play a critical role in resolving inflammation on the surface of the eye’s lens. Published in The American Journal of